Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities

Abroad (travel likely)RecruitingPHASE2

Conditions

Colorectal Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Klinikum St. Marien Amberg, Amberg, Germany

    Contact: Study coordinator (Ludwig Fischer von Weikersthal, Dr.)
  • Charité Campus Virchow Klinikum (CVK), Berlin, Germany

    Contact: Study coordinator (Dominik P Modest, Prof.)
  • Universitätsklinikum Düsseldorf, Düsseldorf, Germany

    Contact: Study coordinator (Christoph Roderburg, Prof.)
  • Kliniken Essen-Mitte, Essen, Germany

    Contact: Study coordinator (Christian Müller, Dr.)
  • Krankenhaus Nordwest, Frankfurt am Main, Germany

    Contact: Study coordinator (Thorsten O. Götze, Prof. Dr.)
  • Hope Hamburg, Hamburg, Germany

    Contact: Study coordinator (Alexander Stein, Prof.)
  • Universitätsmedizin Mainz, Mainz, Germany

    Contact: Study coordinator (Markus Möhler, Prof.)
  • Klinikum München rechts der Isar, München, Germany

    Contact: Study coordinator (Sylvie Lorenzen, Prof.)
  • MVZ für Hämatologie und Onkologie Ravensburg GmbH, Ravensburg, Germany

    Contact: Study coordinator (Tobias Dechow, Prof.)
  • Leopoldina Krankenhaus Schweinfurt, Schweinfurt, Germany

    Contact: Study coordinator (Stephan Kanzler, Prof.)
Study leads
  • Salah Al-Batran, Prof. Dr.

    Study Director

    Institut für Klinische Krebsforschung IKF GmbH

  • Thorsten O. Götze, Prof. Dr.

    Principal Investigator

    Institute of Clinical Cancer Research, UCT - University Cancer Center Frankfurt Krankenhaus Nordwest

  • Markus Möhler, Prof. Dr.

    Principal Investigator

    Johannes Gutenberg-University Clinic Mainz